GENE ONLINE|News &
Opinion
Blog

2022-06-16| Licensing

MorphoSys Thins Pipeline For Potential $1 Billion Deal While Progressing Oncology Ambitions

by Reed Slater
Share To

After a huge deal last year to acquire immuno-oncology targets, MorphoSys announced it is selling licensing rights for two therapies in its pipeline, MOR210 and felzartamab, to Human Immunology BioSciences (HIBio) for a potential $1 billion deal. This news came just a day after MorphoSys announced a clinical trial collaboration with Pfizer and Incyte to study its approved large B-cell lymphoma targeting drug, Monjuvi, in combination with Pfizer’s TTI-622. 

 

Making Big Money To Focus On Cancer Therapies

 

HIBio is a mysterious new company with sparse information on its website. The little information available states it is an autoimmune and inflammatory disease-focused biotech company and MorphoSys’ press release states ARCH Venture Partners and Monograph Capital incubated HIBio. 

MorphoSys’ deal with HIBio consists of a $15 million upfront payment for MOR210, an anti-C5aR1 antibody with potential applications in autoimmune and immuno-oncology targets. HIBio received exclusive rights to MOR210 worldwide except in China, Hong Kong, Macau, Taiwan, and South Korea. 

HIBio also acquired the rights to felzartamab, an anti-CD38 antibody with potential applications in nephropathy, a kind of kidney deterioration, in all the same worldwide locations with the addition of South Korea. 

MorphoSys said it would receive a 15% equity stake in HIBio with up to $1 billion in milestone payments as well as high single-digit or low double-digit percentage royalties on net sales. HIBio will also grant MorphoSys a board seat as part of the deal.

Travis Murdoch, M.D., CEO of HIBio, said, “We are excited that we’ve reached this deal with MorphoSys, which will allow us to realize the potential of felzartamab and MOR210 across multiple autoimmune diseases.”

 

Related Article: Astellas’ $20.5M Deal With GO Therapeutics to Develop Immuno-Oncology Therapeutics

 

Moving Forward With an Oncology-Focused Mindset

 

All this strategic rearranging from MorphoSys stems from a massive $1.7 billion deal with Constellation Pharmaceuticals in June last year to expand its oncology pipeline. The deal netted MorphoSys two clinical-stage therapies, pelabresib and CPI-0209. Pelabresib is now in Phase 3 clinical trials, and CPI-0209 is in Phase 2 clinical trials. 

More recent news in MorphoSys’ oncology development includes a clinical trial collaboration with Pfizer and Incyte. Pfizer will initiate a Phase 1b/2 clinical trial to study the efficacy of Pfizer’s TTI-622, an anti-CD47 antibody, in combination with MorphoSys’ Monjuvi plus lenalidomide to treat relapsed or refractory large B-cell lymphoma. 

MorphoSys struck a $750 million license agreement with Incyte for the development and commercialization of Monjuivi in March 2020, and the FDA approved Monjuvi plus lenalidomide in July 2020. MorphoSys and Incyte will provide Monjuvi for the clinical trial collaboration with Pfizer.

MorphoSys’ big moves will allow more space and funds to shift its focus to immuno-oncology development to justify the $1.7 billion acquisition of Constellation. Lots of moving parts make the host of deals difficult to follow, but as time goes on the dominoes appear to be falling into place for the Germany-based biotech company.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Cancer Research UK and Sosei Heptares Set for First Human Trial of EP4 Antagonist
2022-07-22
Orion Collects $290 Million From Merck in Prostate Cancer Development Collaboration
2022-07-14
ADC Therapeutics and Sobi Sign $435 Million Deal to Expand Blood Cancer Drug’s Market
2022-07-11
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!